INTRODUCTION
The cost of chronic disease management places a tremendous strain on the U.S. health care system. The total estimated cost of diabetes care alone in 2007 was $174 billion, or roughly 10%of total healthcare spending 1 . The electronic personal health record (PHR), defined as an "application through which individuals can access, manage and share their health information…in a private, secure, and confidential environment," 2 has great potential for addressing cost and quality of chronic disease management. Access to effective and tailored patient education, electronic patient-provider communication, and the wealth of clinical information and web-based resources contained within modern PHRs could lead to improvements in chronic disease outcomes through improved patient-centered care and self-management. Few research findings have been published on the value of PHRs in chronic disease management 3 . Three prospective randomized trials evaluated the use of PHRs in the management of type 2 diabetes mellitus (DM) [4] [5] [6] . These studies demonstrated modest but inconsistent improvements in diabetes quality measures when comparing PHR users to non-users. However, because all three studies included additional interventions, such as regular contact with a diabetes care manager, 6 the independent effect of PHR use cannot be determined. Further, small sample sizes in these trials may have limited the ability to detect clinically meaningful differences between study groups. In this study, we explored the actual use of Cleveland Clinic's electronic medical record (EMR)-linked PHR by a large primary care cohort of patients with DM to determine if use of the PHR was associated with improved diabetes quality measures.
METHODS

Participants
We included all primary care patients actively managed DM aged 18-75-years seen in Cleveland Clinic departments of internal medicine and family medicine from July 2008 through June 2009. Diagnosis of diabetes was defined by the presence of appropriate ICD-9 codes (250-250.93, 357.2, 362.0, and 366.41) within the EMR-based longitudinal problem list. Patients with a diagnosis of only "gestational diabetes" or "steroid induced diabetes" were excluded. Patients were considered actively managed if they were seen at least twice in the primary site of their assigned primary care physician during the 12-month period.
PHR Registration and Use
The Cleveland Clinic PHR, MyChart (Epic Inc., Verona, WI), was made available to the general patient population in 2006. As of July 2010, approximately 20-40% of primary care patients utilized the PHR, depending on practice site and physician. Patients were able to register for free access to the internet-based PHR at each office visit, through their primary care provider, or directly through the Cleveland Clinic website. Multiple direct media campaigns to the community efforts were made prior to and throughout the study period (although unrelated to study). Patient access is granted through an identity verification process either in person or via the internet. Once activated, a message is sent to a patient's primary physician informing them that their patient has been granted access to the PHR, at which time the primary care provider can initiate secure PHR communications with the patient, verify medical issues and current medications, and share laboratory results with the PHR-enabled patient.
Once registered, patients require only a secure web browser and internet access to log in and engage in a variety of activities within the PHR. Upon release of patient information by a primary provider, patients with diabetes can access their EMRbased diagnoses and co-morbidities, laboratory and other test results, along with secure messaging through the PHR with their provider. In addition, diabetic patients can access glucometer readings, if entered, a set of diabetes-related health and wellness links, and diabetes specific health reminders (including recommended glycated hemoglobin, urine albumin, and cholesterol testing due dates, recommendation for pneumococcal vaccination, and due dates for diabetic foot and dilated retinal eye exams).
Data Collection
We queried our institutional EMR clinical data repository (Clarity, Epic Inc., Verona, WI) for demographic and clinical data on eligible patients. We queried the PHR usage log to determine number of PHR use days over the study period, along with patient access data for various PHR functions (e.g. number of times a patient reviewed laboratory results, number of messages received from or sent to a patient's primary care physician). All data was de-identified upon extraction and stored in a secure Oracle 9i database (Oracle Corp., Redwood City, CA) for subsequent statistical analysis. Table 1 provides a list of the diabetes quality process and outcome measures. We chose to select the same measures as those used for public reporting in the Better Health Greater Cleveland chronic disease improvement collaborative, as they had been vetted through a multi-organizational approval process and were based on nationally accepted measures.
Quality measures
Data Analysis
Bivariable analyses investigated the crude association between PHR users and non-users with respect to baseline demographic characteristics and diabetes quality measure values.
Categorical variables were analyzed using Fisher's exact test or Pearson's chi-square test. Continuous variables were analyzed using two-sample t-tests or Welch's t-test. Multivariable logistic and linear regression modeling investigated the association between PHR use and diabetes quality measure values. Locally weighted scatterplot smoothing (LOESS) curves were used to assess linearity in the relationship between number of PHR use days and quality measures. Other than the large effect of becoming a PHR user (0 use days to 1 use day), linearity appeared reasonable among users. Thus, the analyses of PHR use has two components: the effect of being a PHR user (nonusers versus patients with ≥1 use day) and among PHR users, the incremental benefit of increasing use days. Adjustment was performed for patient demographic characteristics (age and income as continuous variables and gender, racial/ethnic group [Caucasian versus other], and insurance type [commercial insurance versus other] as categorical variables). As physician use of the PHR is likely to affect patient engagement, adjustment was also made for level of physician engagement (the percentage of the physician's patients from the study sample who used the PHR ≥1 day during the study period).
RESULTS
Patient PHR Use
Of 10,746 eligible patients with DM, 4,036 (37.6%) were enrolled in the PHR by July 2008. The mean number of login days during the 12-month study period was 15 (SD 18) and the median number 9. A histogram of number of login days for PHR users is shown in Figure 1 (Tables 4 and 5 ). An incremental increase in PHR use days by 10 (e.g. 15 days versus 5 days) was associated with slightly greater odds of documented HbA1c testing (OR 1.28, p < 0.01) and only a minimal decrease in HbA1c values (0.02%, p<0.01).
In summary, most quality measures were better, on average, among the group who used the personal health record, but the differences were quite small and of marginal clinical significance. More intensive use of the PHR did not result in any clinically important differences compared to minimal use.
DISCUSSION
Our study provides new insight into the association between PHR adoption and level of use and diabetes quality measures. The PHR evaluated in this study contains a number of features that might assist in diabetes management, including electronic communication with providers, access to diabetes-specific preventive care reminders, and high-quality diabetes-related educational content. However, we found little evidence that use of the PHR substantially improved diabetes quality measures; in our large sample of patients, the improvements we noted were small and of marginal clinical relevance.
As demonstrated in previous studies, 7, 8 we found significant demographic differences in PHR users and non-users, including such factors as lower age and higher incomes. Given these differences, it was not surprising to find better unadjusted diabetes quality measure profiles in PHR users. After adjusting for patient demographic characteristics and level of provider engagement with the PHR, we continued to observe better profiles in PHR users versus non-users for a variety of important diabetes quality measures, such as lower HbA1c and blood pressure values. However, amongst PHR users, we typically found minimal or no association between increasing PHR use days and better diabetes quality measure profiles in the regression models (a poor "exposure-response" relationship). This leads us to suspect that those individuals who take steps to register and login to a PHR program have a different baseline level of engagement with the management of their disease than those who do not. These individuals may be more proactive in seeking health care and more engaged in learning about their medical conditions through a wide variety of media in addition to PHRs, such as through health-related websites or books. They may also be more "health-conscious" regardless of PHR use. We found, for example, lower odds of smoking in PHR users compared to non-users, which we cannot reasonably explain through PHR use.
This type of study design has a number of strengths compared to previous studies. Rather than looking at use or non-use categorically, we gained a more nuanced understanding of potential PHR value by examining the quantity of use among PHR users with diabetes quality measures. The observational approach we employed allowed for sample sizes that are typically unattainable in health informatics randomized trials. Eligible patients also had no knowledge of the study that might have influenced engagement with the PHR.
Among study limitations, this is an association study in which we cannot infer causality between PHR adoption and use and quality of diabetes management. We were unable to capture care received outside of the Cleveland Clinic health system, which might have affected results. However, as patients were seen at least twice at the practice site of their primary care physician during the 12-month study period, we are confident that much or most of the diabetes related care in our patient sample was received at the Cleveland Clinic or documented within the EMR. Our patient population differed from the overall population of the United States. For example, we had few Hispanic patients. This could be important, as health literacy and cultural differences and language background might influence adoption and engagement with the PHR. Finally, some patients may have had surrogates accessing their PHR account, which we could not capture in our PHR data repository. This would have but unknown effects on quality measure profiles for such patients.
To be effective, PHRs need to engage patients on a regular basis and provide tailored, action-oriented advice to improve self-management. The amount of patient PHR use in this study provides evidence that PHRs should be substantially improved to incorporate functionality that is useful and engaging to make the PHR more of an integral, valued tool for diabetes self-management. For example, PHR users only logged into MyChart a median of 9 days, or less than once a month. Next-generation PHRs might engage patients by giving action-oriented advice to patients for self-care via cell phones or through other means 9 . The rapid consumer adoption of iPads, smartphones such as iPhones and Androids, and televisions with the internet built-in opens up possibilities for the future PHR. Such innovations should be validated through future research studies correlating not just use of these tools but also the levels of engagement of these tools with disease outcomes.
